Dear Colleague:

In 2017, nearly 2.3 million cases of chlamydia (CT), gonorrhea (GC), and syphilis were diagnosed in the United States. According to the Centers for Disease Control and Prevention (CDC), this exceeded the 2016 record by over 200,000 cases and marked a fourth year of sharp increases in these sexually transmitted diseases (STDs). To effectively detect and treat disease, it is critical that routine STD screening includes all exposed anatomical sites.¹

For men who have sex with men (MSM), CDC recommends screening for urethral/urinary and rectal GC and CT, and pharyngeal GC (as indicated by exposure) with nucleic acid amplification testing (NAAT). Of note, the rectum and pharynx are the most common sites of GC and CT infections among MSM. These infections are usually asymptomatic and typically occur without a coinciding urethral infection.¹ ² When urine-only screening is performed, up to 90% of rectal GC and 77% of rectal CT infections remain undetected and untreated, thus highlighting the importance of extragenital testing in MSM.³

The California Department of Public Health (CDPH) recommends the following:³³³

- Sexually active people living with HIV – regardless of gender – should receive at least annual GC/CT screening at all exposed sites.⁴

- HIV-negative MSM not using HIV Pre-Exposure Prophylaxis (PrEP) should receive at least annual STD screening at all exposed sites.

- MSM using HIV PrEP should receive quarterly STD screening at all exposed sites.

In addition to provider-collected specimens, patient self-collected swabs are both accurate and acceptable among patients.⁵ ⁶ ⁷ Having patients collect their own specimens could overcome potential barriers to screening such as time constraints and patient/provider communication and discomfort, which might limit provider collection of specimens from extragenital sites.⁸ Standing orders for routine STD screening may further streamline collection for rectal and pharyngeal specimens. The California Prevention Training Center (CAPTC) can assist in implementing routine rectal and pharyngeal STD screening.

¹ Comprehensive screening for STDs should also include serologic tests for syphilis among others as indicated. Please review the California STD Screening Recommendations.

² Testing for oropharyngeal chlamydia is not routinely recommended because its prevalence is generally low.

³ More frequent screening may be appropriate depending on individual risk and local epidemiology.
NAAT for rectal and pharyngeal specimens is not currently approved by the U.S. Food and Drug Administration. However, three commercial laboratories in California have undergone validation and accept NAAT for rectal and pharyngeal specimens: LabCorp, Quest Diagnostics, and Center for Disease Detection. If another laboratory is used by your clinic, the laboratory director can provide guidance on securing approval of NAAT processing for rectal and/or pharyngeal specimens.

Company-specific ordering codes for two widely used laboratories are listed below:

<table>
<thead>
<tr>
<th></th>
<th>Combined GC/CT NAAT Tests</th>
<th>CT test only</th>
</tr>
</thead>
<tbody>
<tr>
<td>RECTAL</td>
<td>188672</td>
<td>16506</td>
</tr>
<tr>
<td>PHARYNGEAL</td>
<td>188698</td>
<td>70051</td>
</tr>
</tbody>
</table>

Current Procedural Terminology (CPT) billing codes:
CT detection by NAAT: 87491; GC detection by NAAT: 87591.

NAAT screening for rectal GC/CT and pharyngeal GC is effective at detecting asymptomatic infections and allows for adequate treatment. Appropriate management, in turn, cures disease, interrupts transmission, and decreases the risk of HIV infection among HIV-negative MSM. With this in mind, CDPH strongly recommends you include routine rectal and pharyngeal STD screening in your practice.

Thank you for your work to improve the sexual health of your patients.

Sincerely,

Eric C. Tang, MD, MPH
Public Health Medical Officer
Sexually Transmitted Diseases Control Branch
California Department of Public Health

Philip J. Peters, MD
Public Health Medical Officer
Office of AIDS
California Department of Public Health

---

iv Laboratory names are provided for informational purposes only. California Department of Public Health does not endorse any company or its products.

v CPT copyright 2008 American Medical Association. All rights reserved.
**Additional Resources (Please click on a resource to be directed to the webpage)**

- **CDPH STD Screening Recommendations**
  [www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CA_STD_Screening-Recs.pdf](http://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CA_STD_Screening-Recs.pdf)
  California Department of Public Health STD screening recommendations, including recommendations for MSM and HIV positive men

- **CDC 2015 STD Treatment Guidelines**
  The Center for Disease Control and Prevention 2015 STD Treatment Guidelines, including guidelines for testing and treatment of rectal gonorrhea and chlamydia

- **National Coalition for STD Directors**
  [www.ncsddc.org/resource/extragential](http://www.ncsddc.org/resource/extragential)
  Resources for providers and laboratories pertaining to extragenital STD testing

- **California Prevention Training Center**
  [www.californiaptc.com](http://www.californiaptc.com)
  Assistance with developing protocols, validation studies, and teaching material related to self-collected specimens

- **STD Clinical Consultation Network**
  [www.stdccn.org](http://www.stdccn.org)
  Online consultation for questions about the evaluation and management of STD cases

- **National STD Curriculum**
  [www.std.uw.edu](http://www.std.uw.edu)
  National Network of STD Prevention Training Centers (NNPTC)’s free online STD curriculum and question bank. Offers continuing medical education credits.

- **Telephone HIV Consultation hotlines:**
  HIV/AIDS management: 800-933-3413
  PrEP phone consultation: 855-448-7737
  PEP phone consultation: 888-448-4911


